Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
HRMY
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Quote Panel
Key Metrics
Forecast
390%2026-Revenue
464%2026-EPS
362%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
33.00(2.15%)
Number of analyst
1
Last analyst upgrade/downgrade
UBS
initialisePrevious: Not converted
2024-09-09
Now: Buy
Citigroup
initialisePrevious: Not converted
2024-06-20
Now: Buy
Jefferies
upgradePrevious: Not converted
2022-10-14
Now: Buy
Zacks Investment Research
upgradePrevious: Not converted
2022-04-26
Now: Hold
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
NASDAQ
0.24Ā ( 0.76%)
Relative Strenght
17
Volume Buzz
-80%
Earning Acce
No
Dist 52w H.
22%Relative Strength
HRMY
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Earnings Growth
YoY
Current
Estimates
Q3.23
-21%
0.75
vsĀ 0.95
Q4.23
-43%
0.45
vsĀ 0.79
Q1.24
+40%
0.67
vsĀ 0.48
Q2.24
-64%
0.2
vsĀ 0.56
Q3.24
+5%
0.79
vsĀ 0.75
Q4.24
+89%
0.85
vsĀ 0.45
Q1.25
+16%
0.78
vsĀ 0.67
Q2.25
+240%
0.68
vsĀ 0.2
Q3.25
-6%
0.74
vsĀ 0.79
Q4.25
+6%
0.9
vsĀ 0.85
Sales Growth
YoY
Current
Estimates
Q3.23
+37%
160.3MĀ vsĀ 117.2M
Q4.23
+31%
168.4MĀ vsĀ 128.3M
Q1.24
+30%
154.6MĀ vsĀ 119.1M
Q2.24
+29%
172.8MĀ vsĀ 134.2M
Q3.24
+16%
186MĀ vsĀ 160.3M
Q4.24
+20%
201.3MĀ vsĀ 168.4M
Q1.25
+19%
184.7MĀ vsĀ 154.6M
Q2.25
+16%
200.5MĀ vsĀ 172.8M
Q3.25
+19%
220.5MĀ vsĀ 186M
Q4.25
+17%
235.9MĀ vsĀ 201.3M
Return on Equity
QoQ
Q1.23
+7%
0.07
vsĀ 0.12
Q2.23
+7%
0.07
vsĀ 0.07
Q3.23
+8%
0.08
vsĀ 0.07
Q4.23
+6%
0.06
vsĀ 0.08
Q1.24
+7%
0.07
vsĀ 0.06
Q2.24
+2%
0.02
vsĀ 0.07
Q3.24
+8%
0.08
vsĀ 0.02
Q4.24
+8%
0.08
vsĀ 0.08
Q1.25
+6%
0.06
vsĀ 0.08
Q2.25
+5%
0.05
vsĀ 0.06
Institutionnal Ownership
QoQ
Q1.23
224
224
vsĀ 244
-8%
Q2.23
214
214
vsĀ 224
-4%
Q3.23
210
210
vsĀ 214
-2%
Q4.23
225
225
vsĀ 210
7%
Q1.24
212
212
vsĀ 225
-6%
Q2.24
223
223
vsĀ 212
5%
Q3.24
235
235
vsĀ 223
5%
Q4.24
251
251
vsĀ 235
7%
Q1.25
272
272
vsĀ 251
8%
Q2.25
270
270
vsĀ 272
-1%
businesswire.com
8 hours ago
businesswire.com
8 hours ago
seekingalpha.com
16 hours ago
seekingalpha.com
16 hours ago